Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines

  title={Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines},
  author={Zhidong Hu and Weimin Jiang and Ling Gu and Dan Qiao and Tsugumine Shu and Douglas Bruce Lowrie and Shuihua Lu and Xiao-Yong Fan},
  journal={Journal of Molecular Medicine},
  pages={1685 - 1694}
In an earlier study, a novel Sendai virus–vectored anti-tuberculosis vaccine encoding Ag85A and Ag85B (SeV85AB) was constructed and shown to elicit antigen-specific T cell responses and protection against Mycobacterium tuberculosis (Mtb) infection in a murine model. In this study, we evaluate whether the immune responses induced by this novel vaccine might be elevated by a recombinant DNA vaccine expressing the same antigen in a heterologous prime-boost vaccination strategy. The results showed… 
4 Citations
The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector
This review outlines approaches for developing vaccines against the new SARS-CoV-2 coronavirus that are based on non-pathogenic viral vectors, since it can be administered intranasally and induce a mucosal immune response that strengthens the antiviral barrier in the respiratory tract and provides reliable protection against infection.
Recent progress in the design of DNA vaccines against tuberculosis.
This review focuses on the design and delivery of novel DNA-based vaccines against TB and summarize investigations on specific mycobacterial antigens and chimeric combinations in animal models.
Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1− CD4+ T cells
It is demonstrated that mucosal BCG vaccination significantly improves protection over systemic BCG and this correlates with a novel population of BCG-induced lung tissue-resident CD4+ T cells.
Preclinical Progress of Subunit and Live Attenuated Mycobacterium tuberculosis Vaccines: A Review following the First in Human Efficacy Trial
Preclinical vaccine work in the last 5 years is reviewed with focus on those tested against M. tb challenge in relevant animal models, including recombinant BCG strains, genetically attenuated M.tb and naturally attenuated mycobacteria strains, novel methods of immunogenic antigen discovery, and broader selection of viral vectors are reviewed.


Boosting BCG-primed mice with chimeric DNA vaccine HG856A induces potent multifunctional T cell responses and enhanced protection against Mycobacterium tuberculosis
It was shown that repeated immunization with HG856A gave modest protection against M. tuberculosis challenge infection and significantly boosted the immune protection primed by BCG vaccination, confirming the potential of chimeric DNA vaccine HG8 56A as an anti-TB vaccine candidate.
Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis.
  • Q. You, Yongge Wu, +9 authors W. Kong
  • Biology, Medicine
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2012
This study demonstrates the potential of multiple heterologous viral booster vaccines, although the exact correlates of protection and optimal regimens should be further investigated for the rational design of future vaccine strategies.
Sendai Virus Mucosal Vaccination Establishes Lung-Resident Memory CD8 T Cell Immunity and Boosts BCG-Primed Protection against TB in Mice
It is suggested that CD8+ TRM cells that arise in lungs responding to this mucosal vaccination might help to protect against TB, and SeV85AB holds notable promise to improve BCG’s protective efficacy in a prime-boost immunization regimen.
Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers1
Describing cell-mediated immune responses induced by different prime-boost combinations where all vectors encode a multiepitope string fused to the pre-erythrocytic Ag thrombospondin-related adhesion protein shows that these different vectors need to be used in a specific order for an optimal ex vivo IFN-γ response.
Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guérin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara1
It is shown that recombinant modified vaccinia virus Ankara, expressing Mycobacterium tuberculosis Ag 85A (M.85A), strongly boosts bacille Calmette-Guérin (BCG)-induced Ag85A specific CD4+ and CD8+ T cell responses in mice, which support further evaluation of mucosally targeted prime-boost vaccination approaches for tuberculosis.
Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques.
The feasibility of inducing antigen-specific T-cell responses by SeV vaccination even in the host with pre-existing anti-SeV neutralizing antibodies is suggested.
Elicitation of Both Anti HIV-1 Env Humoral and Cellular Immunities by Replicating Vaccinia Prime Sendai Virus Boost Regimen and Boosting by CD40Lm
The results suggest that the m8Δ prime/SeV boost regimen in conjunction with CD40Lm expression could be used as an immunization platform for driving both potent cellular and humoral immunities against pathogens such as HIV-1.
The Profile of T Cell Responses in Bacille Calmette–Guérin-Primed Mice Boosted by a Novel Sendai Virus Vectored Anti-Tuberculosis Vaccine
The data strongly suggest that the enhanced immune protection induced by SeV85AB boosting was associated with establishment of an increased capacity to recall antigen-specific IL-2-mediated T cell responses and confirms this Sendai virus vector system as a promising candidate to be used in a heterologous prime-boost immunization regimen against TB.
Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies.
Vaccination of antibody-deficient mice showed that vaccine-induced RSV F-specific T cells were sufficient for protective immunity, and vaccination with rSeV F is sufficient to induce protective T cell immunity against RSV in mice.
On DNA vaccines and prolonged expression of immunogens
  • T. Hanke
  • Medicine
    European journal of immunology
  • 2006
This commentary discusses the results of immunization of BALB/c mice intramuscularly with a DNA vaccine encoding HBsAg, the safety of plasmid DNA‐vectored genetic vaccines in general, the use of DNA vaccines expressingHBsAg for the treatment of chronic hepatitis and the consequences of prolonged immunogen expression for the development of protective immune responses.